Craft

Opiant Pharmaceuticals

Stock Price

$20.6

2023-03-02

Market Capitalization

$108.8 M

2023-03-02

Revenue

$47.8 M

FY, 2021

Opiant Pharmaceuticals Summary

Company Summary

Overview
Opiant Pharmaceuticals is a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company's pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. Opiant Pharmaceuticals is also focused on other treatment opportunities.
Type
Public
Status
Active
Founded
2009
HQ
Santa Monica, CA, US | view all locations
Website
http://www.opiant.com
Cybersecurity rating
Sectors

Key People

  • Roger Crystal

    Roger Crystal, President, Chief Executive Officer, Director

    • Ann MacDougall

      Ann MacDougall, Independent Director

      • Craig Collard

        Craig Collard, Independent Director

        • Phil Skolnick

          Phil Skolnick, Chief Scientific Officer

          LocationsView all

          3 locations detected

          • Santa Monica, CA HQ

            United States

            233 Wilshire Blvd #280

          • Santa Monica, CA

            United States

            401 Wilshire Blvd 12th Floor

          • London, England

            United Kingdom

            One Kingdom St, Paddington

          Opiant Pharmaceuticals Financials

          Summary Financials

          Revenue (Q3, 2022)
          $173.9K
          Net income (Q3, 2022)
          ($9.9M)
          Cash (Q3, 2022)
          $35.4M
          EBIT (Q3, 2022)
          ($9.6M)
          Enterprise value
          $87.8M

          Footer menu